Praxis 仅公告二季度业绩电话会时间，尚未披露业绩或经营增量

Thursday, August 6, 2026
.
The Company will host a conference call and a live webcast to review the second quarter financial results and provide a corporate update on
Thursday, August 6, 2026
, at
8:30 am ET
, which can be accessed by visiting this
registration link
. The live webcast will also be available through the
Events & Presentations
page of the Investors + Media section of the company’s website
www.praxismedicines.com
.
A replay of the second quarter earnings webcast will be available on Praxis’
Events & Presentations
page of the company’s website after each event for approximately 90 days.
About Praxis
Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on
Facebook
,
Instagram
,
LinkedIn
and
Twitter/X
.
Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452

Media Contact:
Dan Ferry
LifeSci Advisors
Daniel@lifesciadvisors.com
617-430-7576